Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mylan Strikes $1B Deal for Dermatology Drugs

By Drug Discovery Trends Editor | May 16, 2016

​Mylan announced on Friday it agreed to spend up to $1 billion, an initial payment of $950 million in cash followed by a contingency payment of $50 million, to acquire a slew of topical skin medications from Renaissance Acquisition Holdings, an investment fund focusing on pharmaceutical assets.

The deal gives Mylan “a portfolio of more than two dozen approved drugs and a pipeline of two dozen more, as well as a sales organization it says is tapped into the dermatology docs,” according to FiercePharma.

Reuters adds that Renaissance raked in an estimated $350 million in revenue last year. Dermatology drugs are prescribed for conditions like plaque psoriasis or fungal infections. Some of Renaissance’s assets include cold-sore ointment  Denavir and the generic versions of acyclovir and Olux Foam.

Mylan’s acquisition adds to its growing dermatology business after it bought Swedish drug maker Meda February through a $7.2 billion cash and stock deal. Meda was tasked with handling European sales for EpiPen, Mylan’s emergency shot for allergic reactions and best-selling branded product, according to another Reuters report.

The market for dermatological drugs like psoriasis treatments looks promising. A recent report from research and consulting firm GlobalData said that treatments like Eli Lilly’s psoriasis treatment, Taltz, could bring in an excess of $1 billion sales by 2022.

The acquisition is expected to close by the end of the third quarter. Mylan’s shares were up by 0.91 percent in early-afternoon trading. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE